Euvolemic And Hypervolemic Hyponatremia Therapeutics
1. Vaprisol patent expiration
Treatment: Method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with hypervolemic hyponatremia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5723606 | CUMBERLAND | Condensed benzazepine derivative and pharmaceutical composition thereof |
Dec, 2019
(6 years ago) | |
Drugs and Companies using CONIVAPTAN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 December, 2005
Dosage: INJECTABLE
More Information on Dosage
VAPRISOL family patents
